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Abstract
The development of acquired protective immunity to Plasmodium falciparum infection in young
African children is considered in the context of three current strategies for malaria prevention:
insecticide-impregnated bed nets or curtains, anti-sporozoite vaccines and intermittent preventive
therapy. Evidence is presented that each of these measures may permit attenuated P. falciparum
blood-stage infections, which do not cause clinical malaria but can act as an effective blood-stage
"vaccine". It is proposed that the extended serum half-life, and rarely considered liver-stage
prophylaxis provided by the anti-folate combination sulphadoxine-pyrimethamine frequently lead
to such attenuated infections in high transmission areas, and thus contribute to the sustained
protection from malaria observed among children receiving the combination as intermittent
preventative therapy or for parasite clearance in vaccine trials.
Background
A significant reduction in the intolerable global burden of
malaria morbidity and mortality is unlikely without the
large-scale implementation of effective and sustainable
prevention. However, it has been recognized for more
than a decade that measures which reduce the level of
exposure may interfere with the natural acquisition of
immunity to malaria [1]. Direct testing of this hypothesis
has been hampered by the lack of validated immunologi-
cal markers of protection.
The suggestion that any short-term protection afforded by
insecticide-impregnated materials (IIM) may be followed
by longer-term increased susceptibility, or "rebound",
applies equally to other interventions that reduce or pre-
vent infection. For this reason, clinical trials of malaria
vaccines and of intermittent preventive therapy (IPT) have
used extended post-intervention follow-up to detect any
rebound of excess malaria among recipients of the inter-
vention. Published controlled trials of preventative inter-
ventions including IIM, IPT and vaccination are
considered, and findings discussed in the light of evidence
that low-dose blood stage infections of Plasmodium falci-
parum elicit effective and sustained immunity against clin-
ical malaria [2].
It is hypothesized that the antimalarial sulphadoxine-
pyrimethamine (SP), because of its long serum half-life
and its activity against developing hepatic parasite stages,
generates low dose blood stage inocula and attenuated
infections, and can thus act as an ideal blood-stage vac-
cine when used for malaria prevention in highly endemic
areas.
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Intervention 1: Insecticide-treated curtains in 
Burkina Faso
An ambitious programme initiated in 1994 to provide a
high-coverage of IIM in Oubritenga Province, Burkina
Faso, was associated with a reduction in entomological
inoculation rate of >90% [3]. All-cause mortality fell over
six years by at least 19% with no evidence from long-term
follow-up that mortality was shifted to older-aged chil-
dren [4]. Chloroquine treatment failure rates did not dif-
fer between protected and unprotected intervention
villages [5].
In the absence of immunological markers, the acquisition
of immunity to malaria may be demonstrated by the abil-
ity to clear resistant parasites under treatment with a fail-
ing drug [6,7]. Diallo and colleagues [8] measured
parasite clearance rates after chloroquine treatment
among 409 children in Oubritenga infected with parasites
of the pfcrt-76T chloroquine resistant genotype, compar-
ing those under lifelong IIM protection, with those with-
out IIMs in their village. IIM-protected children were
significantly more likely to successfully clear resistant par-
asites after chloroquine treatment, compared to unpro-
tected children (OR 1.80, 95% C.I. 1.15 – 2.80; P = 0.01).
After stratification, children under three years of age
remained significantly better at clearing resistant parasites
than their unprotected peers, whereas children IIM-pro-
tected and unprotected at a later age were equally able to
clear their infections. Thus, in the fourth and fifth years of
life, unprotected children had levels of immunity similar
to those enjoyed by children who have been protected by
IIM.
These findings suggest that IIM-protected children in
Burkina Faso commonly acquired protective immunity
earlier. This may be because the protection afforded by
IIM delays, on average, the age at which children are first
challenged by P. falciparum infections. Older children are
more likely to mount an effective immune response, pre-
venting further progression of disease. The process of
acquiring immunity to malaria in these children is likely
to involve interplay between:
￿ the risk of infection with P. falciparum leading to a dis-
ease episode
￿ the age at which children first encounter infection.
Intervention 2: Anti-sporozoite vaccines
The anti-sporozoite P. falciparum vaccine RTS, S is now
under extensive testing in clinical trials in sub-Saharan
Africa. Phase II controlled trials of the vaccine in Gambian
men [9] and Mozambiquan children [10,11] demon-
strated protective efficacy of 30 – 45% against P. falci-
parum  parasitaemia, but differed in one remarkable
respect. Vaccine-elicited parasitological benefit was tran-
sient in Gambian men, having diminished within 16
weeks of vaccination, whereas RTS, S-vaccinated children
in Mozambique enjoyed a reduction in malaria episodes
through 18 months of follow-up [11]. A parsimonious
explanation for this discrepancy in the observed duration
of protection afforded by RTS, S is that vaccinated children
gained enhanced anti-parasite immunity, compared to
controls, that the men already enjoyed irrespective of vac-
cination status. As RTS, S appears to offer protection to
only a proportion of those vaccinated, it is also likely that
incomplete protection in some vaccinated individuals
impairs release of post-liver-stage merozoites without
completely preventing it [12]. This may lead to attenuated
blood-stage parasite infections, and support the develop-
ment of blood-stage immunity [2]. Thus, by partially and
transiently preventing maturation of liver-stage parasites,
RTS, S may be eliciting effective anti-blood-stage immu-
nity in a proportion of vaccinated children, but not in
adults.
The development of protective blood-stage immunity by
this proposed mecanism would be dependent on:
￿ the likelihood of natural parasite challenge during the
transient period of anti-sporozoite protection
￿ the level of immunity at the time of vaccination.
Intervention 3: Intermittent preventive 
treatment
In a placebo-controlled trial in 700 infants in Tanzania,
Schellenberg et al [13,14] investigated IPT with SP, admin-
istered at 3, 6 and 9 months of life at the time of normal
scheduled immunizations. This study demonstrated 59%
efficacy (95% C.I. 41–72%) against clinical episodes of
malaria up to 12 months of age. Extended follow-up to
age 2 years, a period of 15 months after the last dose of
IPT, demonstrated persistent protection of 36% (95% C.I.
11–53%) against clinical malaria. The authors conclude
that, in this setting, IPT in infants could be facilitating the
development of protective immunity in these children.
Under moderate to high transmission intensity, it can be
imagined that a subset of IPT recipients are naturally chal-
lenged by P. falciparum infections during a period of wan-
ing blood levels of the component drugs of SP. This could
readily lead to attenuated blood-stage infections that do
not flourish, and thus do not cause clinical malaria, but
persist at low density, providing a challenge capable of
eliciting protective immunity. This explanation is consist-
ent with the results of a placebo-controlled clinical trial of
the P. falciparum blood-stage vaccine Combination B, in
which 120 participants (aged between five and nine years)
were randomized into placebo or vaccine arms, with orMalaria Journal 2007, 6:161 http://www.malariajournal.com/content/6/1/161
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without pre-intervention clearance of parasitaemia by SP
[15]. A crude, uncorrected comparison of parasite preva-
lence during 18 weeks of follow-up in the two placebo
arms suggests that SP acts like a very good vaccine (OR
0.167; 95% C.I. 0.044 – 0.599; P = 0.003). This analysis is
confounded by both a higher prevalence of pre-treatment
parasitaemia in the placebo arm that did not receive SP
(37% vs 17%), and by the several weeks of effective
prophylaxis afforded by SP, but nevertheless is consistent
with the hypothesis presented here: that SP can enhance
the acquisition of immunity in children under intense
infection pressure. This effect was not observed in a recent
study in adult vaccinees and controls, some of whom were
given a prophylactic dose of SP prior to surveillance [16].
Key parameters of SP-enhanced immunity appear to be:
￿ the probablility of infection during the period of effec-
tive drug levels
￿ the level of immunity before IPT/chemoprophylaxis is
given
Hypothesis
Having presented evidence supporting the notion that
low dose P. falciparum infections enhance development of
immunity, it is now proposed that presumptive adminis-
tration of SP to young children in moderate to high trans-
mission areas can accelerate their acquisition of protective
immune responses. This occurs because, firstly, the elimi-
nation half-lives of sulphadoxine (11 days) and pyrimeth-
amine (3 days) in serum provide extended
pharmacological protection against the emergence of new
blood-stage infections from the liver, but become permis-
sive of such new infections as serum drug levels wane in
due course. Secondly, SP provides a level of causal proph-
ylaxis against liver-stage infection that is poorly under-
stood [17-19]. Liver-stage malaria parasites are
particularly dependent on folate synthesis as a single spo-
rozoite nucleus must initiate a staggering 14 mitotic divi-
sions over 7–14 days to release >104 progeny merozoites
into the blood. It is thus likely hepatic stages are exqui-
sitely sensitive to anti-folate drugs such as SP, but no
detailed studies have been published.
In particular, it is unknown whether resistance-associated
mutations in the pfdhfr and pfdhps loci also protect hepatic
parasites against SP, and it is a plausible possibility that SP
remains effective against so called "resistant" parasites
during rapid hepatic stage DNA replication, prior to fur-
ther expansion of the total parasite burden during blood-
stage infection. This offers an explanation for the contin-
ued utility of SP in preventative applications even where
clinical cases commonly fail under SP treatment.
Testing the hypothesis
Low-dose blood-stage infections enhance the acquisition
of immunity against clinical malaria, perhaps partly by
thwarting the immune suppression effects of clinical dis-
ease [20]. Sustained benefit is profoundly dependent on
the likelihood of natural challenge during the period of
protection (and thus on transmission intensity), on previ-
ous parasite exposure and on the level of immunity of the
individual. Testing this hypothesis will require careful
analysis of the impact of drug suppression on the acquisi-
tion of immunity in children with and without prior
malaria infections.
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